Sino Biopharmaceutical Limited
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
6/10
|
23.35 | 35.42 | -34.07% | 46.76 | -50.06% |
| P/S |
|
2.08 | 7.59 | -72.61% |
|
|
| P/BV |
|
1.43 | 3.68 | -61.29% |
|
|
| P/FCF |
|
13.53 | 55.41 | -75.57% |
|
|
| Ev/Ebitda |
|
11.92 | 2.91 | 309.81% |
|
|
| Ev/S |
|
2.18 | 23.72 | -90.79% |
|
|
| Ev/FCF |
|
13.11 | 63.79 | -79.44% |
|
|
| E/P |
|
0.0395 | 0.0326 | 21.12% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
8/10
|
25.24 | -11.9 | -312.07% | 35.38 | -28.67% |
| ROE |
|
7.74 | 5.19 | 49.32% |
|
|
| ROA |
|
3.65 | 3.47 | 5.29% |
|
|
| ROIC |
|
0 | 0 | 0% |
|
|
| ROS |
|
8.9 | -11.49 | -177.48% |
|
|
| ROCE |
|
0 | 6.04 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
7/10
|
1.94 | 0.7755 | 150.8% | 1.7 | 14.64% |
| Nеt Debt/Ebitda |
|
0.38 | 0.0128 | 2878.34% |
|
|
| Debt/Ratio |
|
0.222 | 0.1229 | 80.7% |
|
|
| Debt/Equity |
|
1.53 | 0.8001 | 90.79% |
|
|
| Debt/Net Income |
|
6.06 | 1.76 | 244.52% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
7.08/10
|
2.83 | 2.42 | 17.03% | 1.67 | 69.45% |
| Number of years of dividend growth |
|
0 | 1.21 | -100% |
|
|
| DSI |
|
0.7857 | 0.563 | 39.57% |
|
|
| Average dividend growth |
|
6.53 | 3.2 | 103.9% |
|
|
| Average percentage for 5 years |
|
1.67 | 1.82 | -8% |
|
|
| Average percentage for payments |
|
49.95 | 23.96 | 108.48% |
|
|
| Difference from average difference in sector |
|
0.4119 |
|
|
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % |
|---|---|---|---|---|
| Growth impulse Revenue 5 years |
2/10
|
8.11 | 19.4 | -58.2% |
| Growth impulse Ebitda 5 years |
|
4.59 | -44.8 | -110.25% |
| Growth impulse Net Income 5 years |
|
-13.85 | 80.79 | -117.14% |
| Growth impulse FCF 5 years |
|
21.48 | 76.43 | -71.9% |
| Growth impulse EPS 5 years |
|
-26.15 | -116.84 | -77.62% |
IP Score
4.86/10
